MindFX Science Inc cannot indemnify against any claims made in the following abstracts or derived from them. So it would be best to bring any text from these abstracts to your physician before using the products if you have personal concerns or individual health problems. 

 

VINPOCETINE

 

 

 

 

 

Vinpocetine supports healthy brain function by facilitating blood flow through the microcapillaries of the central nervous system. 

Vinpocetine has only begun to receive attention in the U.S. within the past few years. Outside the U.S., particularly in Europe, it has been used for several years in connection with brain health. Vinpocetine is derived from vincamine of the lesser periwinkle ( Vinca minor L ). It was approved by the FDA in July 1999 and hits popularity as an ingredient in brain nutraceuticals is growing. MindFX Science uses the finest grade in its MindFX Performance and NeuroCharge products.Vinpocetine is a substance that increases blood flow to the brain, hence it is a vasodilator. Vasodilation is achieved by improving the rheological properties of blood through inhibition of platelet aggregation and by increasing the deformability of red blood cells. Blood viscosity and resistance of blood flow in cerebral vessels are reduced, allowing the circulation of more oxygen to brain cells, thereby promoting lucidity and mental alertness.

Vinpocetine also inhibits phosphidiesterase, the enzyme that breaks down ATP to ADP and AMP. Since ATP is the energy that fuels biochemical reactions, inhibiting phosphidiesterase increases ATP levels in cells. This means an increase in energy is available to neurons. Increased metabolism in neurons is indicated by increased glucose metabolism in the brain brought on by increased blood flow due to vinpocetine.

The actions of vinpocetine are both preventative and specific. Its reported anti-aeschemic activity, enhancement of blood flow and cerebral circulation are positives for maintenance of overall brain health. An increase in the rate of ATP synthesis and consumption of cerebral glucose would be considered more system specific. In both cases, the actions of vinpocetine may help in the management of Alzheimer’s or Parkinson’s disease and both have been areas of clinical studies with vinpocetine.

 

 

 

 

Miyazaki M. The effect of a cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiology 1995 Jan;46(1):53-8. Department of Internal Medicine, Rohju Sanatorium, Osaka, Japan. Changes in cerebral vascular resistance were examined in patients with cerebral circulatory diseases by the Doppler ultrasonic technique after administration of a cerebral vasodilator, vinpocetine, for two months. Continuous index (CI) and pulsatility index (PI) of the blood flow pattern in the internal carotid artery were used as objective parameters for changes in cerebral vascular resistance. 1. The CI and PI changed significantly after administration of the drug; ie, the CI increased while the PI decreased. 2. An inverse correlation was noted between the rate of change of the CI (delta CI) and that of the PI (delta PI). 3. The results suggest that measurement of the CI and PI by the Doppler ultrasonic technique is useful in investigating the effect of drugs on the cerebral circulation.Horvath B, Marton Z, Halmosi R, Alexy T, Szapary L, Vekasi J, Biro Z, Habon T, Kesmarky G, Toth K. In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin Neuropharmacol 2002 Jan-Feb;25(1):37-42. First Department of Medicine, Division of Cardiology, University of Pecs‚ School of Medicine, Pecs, Hungary. Oxygen-free radicals play an important role in several physiologic and pathophysiologic processes. In pathologic circumstances, they can modify and damage biologic systems. Because oxygen-free radicals are involved in a wide range of diseases (cerebrovascular, cardiovascular, etc.), scavenging these radicals should be considered as an important therapeutic approach. In our in vitro study, we investigated the antioxidant capacity of three drugs: pentoxiphylline (Sigma Aldrich, St. Louis, MO, USA) piracetam (Sigma Aldrich), and vinpocetine (Richter Gedeon RT, Budapest, Hungary). Phenazine methosulphate was applied to generate free radicals, increasing red blood cell rigidity. Filtration technique and potassium leaking were used to detect the cellular damage and the scavenging effect of the examined drugs. According to our results, at human therapeutic serum concentration, only vinpocetine (Richter Gedeon RT) had significant (p < 0.01) scavenging activity with a protective effect that increased further at higher concentrations. Pentoxiphylline (Sigma Aldrich) and piracetam (Sigma Aldrich) did not have significant antioxidant capacity at therapeutic concentrations, but increasing their concentrations (pentoxiphylline at 100-times, and piracetam at 10-times higher concentrations) led to a significant (p < 0.01) scavenger effect. Our findings suggest that this pronounced antioxidant effect of vinpocetine and even the milder scavenging capacity of pentoxiphylline and piracetam may be of value in the treatment of patients with cerebrovascular disorders, but merits further investigation.